|
Q3 2024
|
90 |
169,299 |
LENZ, CTNM, LLY, UNH
|
13F-HR
|
11/14/2024 |
000110465924118494 |
|
Q2 2024
|
97 |
246,059 |
LLY, LENZ, CONTINEUM THERA, UNH
|
13F-HR
|
8/13/2024 |
000110465924088729 |
|
Q1 2024
|
92 |
254,377 |
LENZ THERAPEUTICS, LLY, BOUNDLESS BIO INC, UNH
|
13F-HR
|
5/14/2024 |
000110465924061089 |
|
Q4 2023
|
104 |
232,224 |
LLY, UNH, MRK, JNJ
|
13F-HR
|
2/14/2024 |
000110465924022582 |
|
Q3 2023
|
123 |
513,530 |
BMRN, LLY, OPCH, CNMD
|
13F-HR
|
11/14/2023 |
000110465923117467 |
|
Q2 2023
|
121 |
599,779 |
RCM, EVH, PRVA, APLS
|
13F-HR
|
8/11/2023 |
000110465923090436 |
|
Q1 2023
|
118 |
520,300 |
EVH, RCM, SWAV, UNH
|
13F-HR
|
5/12/2023 |
000110465923059619 |
|
Q4 2022
|
120 |
516,778 |
EVH, HQY, RCM, BMRN
|
13F-HR
|
2/10/2023 |
000110465923018063 |
|
Q3 2022
|
109 |
507,582 |
UNH, HQY, BMRN, EVH
|
13F-HR
|
11/10/2022 |
000110465922116875 |
|
Q2 2022
|
112 |
496,292 |
UNH, HQY, RCM, NARI
|
13F-HR
|
8/15/2022 |
000110465922090800 |
|
Q1 2022
|
106 |
563,339 |
UNH, HQY, NARI, ATRC
|
13F-HR
|
5/10/2022 |
000110465922058211 |
|
Q4 2021
|
108 |
664,448 |
ARNA, EFTR, OCDX, SYNH
|
13F-HR
|
2/11/2022 |
000110465922019952 |
|
Q3 2021
|
127 |
1,202,376 |
EFTR, EVH, SYNH, RCUS
|
13F-HR
|
11/15/2021 |
000110465921138704 |
|
Q2 2021
|
127 |
1,235,959 |
TFX, EVH, ATRC, OCDX
|
13F-HR
|
8/16/2021 |
000110465921105743 |
|
Q1 2021
|
113 |
1,319,058 |
AVIR, EVH, NVAX, OCDX
|
13F-HR
|
5/14/2021 |
000110465921066370 |
|
Q4 2020
|
97 |
1,419,099 |
AVIR, ARVN, TNDM, TDOC
|
13F-HR
|
2/12/2021 |
000110465921021495 |
|
Q3 2020
|
88 |
1,163,138 |
IMMU, PPD, LH, PTCT
|
13F-HR
|
11/13/2020 |
000110465920125051 |
|
Q2 2020
|
191 |
1,089,396 |
APRE, HRC, PTCT, FOLD
|
13F-HR
|
8/13/2020 |
000110465920094408 |
|
Q1 2020
|
65 |
520,942 |
APRE, TDOC, BMRN, BSX
|
13F-HR
|
5/13/2020 |
000110465920060525 |
|
Q4 2019
|
65 |
670,201 |
APRE, TDOC, BSX, TNDM
|
13F-HR
|
2/12/2020 |
000110465920018421 |
|
Q3 2019
|
63 |
579,649 |
TDOC, FOLD, TNDM, APLS
|
13F-HR
|
11/14/2019 |
000110465919063907 |
|
Q2 2019
|
92 |
836,298 |
SWAV, FOLD, APLS, ARRY
|
13F-HR
|
8/14/2019 |
000110465919045891 |
|
Q1 2019
|
106 |
831,389 |
FOLD, AERIE PHARMACEUTIC, ALNY, APLS
|
13F-HR
|
5/14/2019 |
000110465919029204 |
|
Q4 2018
|
104 |
735,642 |
FOLD, AERIE PHARMACEUTIC, ALNY, TDOC
|
13F-HR
|
2/12/2019 |
000110465919007490 |
|
Q3 2018
|
168 |
941,926 |
FOLD, AERIE PHARMACEUTICALS, APLS, ALNY
|
13F-HR
|
11/14/2018 |
000110465918068465 |
|
Q2 2018
|
67 |
894,436 |
FOLD, AERIE PHARMACEUTIC, APLS, LJPC
|
13F-HR
|
8/13/2018 |
000110465918051494 |
|
Q1 2018
|
68 |
912,062 |
FOLD, APLS, LJPC, BMRN
|
13F-HR
|
5/15/2018 |
000110465918033268 |
|
Q4 2017
|
67 |
800,302 |
FOLD, APLS, ACAD, NVS
|
13F-HR
|
2/13/2018 |
000110465918009094 |
|
Q3 2017
|
62 |
776,312 |
FOLD, PFE, NVS, ACAD
|
13F-HR
|
11/14/2017 |
000110465917068399 |
|
Q2 2017
|
61 |
914,419 |
PFE, JNJ, MRK, NVS
|
13F-HR
|
8/14/2017 |
000110465917051739 |
|
Q1 2017
|
65 |
856,296 |
MRK, JNJ, PFE, NBIX
|
13F-HR
|
5/15/2017 |
000110465917032751 |
|
Q4 2016
|
55 |
902,673 |
MRK, PFE, LLY, CELG
|
13F-HR
|
2/10/2017 |
000110465917008034 |
|
Q3 2016
|
56 |
1,018,707 |
MRK, PFE, CELG, LLY
|
13F-HR
|
11/10/2016 |
000110465916156249 |
|
Q2 2016
|
64 |
968,425 |
NBIX, MRK, PFE, LLY
|
13F-HR
|
8/12/2016 |
000110465916139204 |
|
Q1 2016
|
81 |
2,068,198 |
CELG, GILD, BMRN, AMGN
|
13F-HR
|
5/13/2016 |
000110465916120779 |
|
Q4 2015
|
75 |
2,345,362 |
GILD, ALXN, BMRN, CELG
|
13F-HR
|
2/12/2016 |
000110465916096363 |
|
Q3 2015
|
77 |
2,182,912 |
BIIB, GILD, CELG, REGN
|
13F-HR
|
11/13/2015 |
000110465915078664 |
|
Q2 2015
|
91 |
2,397,497 |
BIIB, GILD, CELG, BMRN
|
13F-HR
|
8/13/2015 |
000110465915059367 |
|
Q1 2015
|
77 |
2,633,516 |
BIIB, BMRN, CELG, GILD
|
13F-HR
|
5/14/2015 |
000110465915038098 |
|
Q4 2014
|
64 |
2,229,435 |
BIIB, AMGN, CELG, BMRN
|
13F-HR
|
2/13/2015 |
000110465915010210 |
|
Q3 2014
|
66 |
2,376,271 |
BIIB, AMGN, GILD, CELG
|
13F-HR
|
11/13/2014 |
000110465914080151 |
|
Q2 2014
|
64 |
2,360,081 |
BIIB, AMGN, GILD, CELG
|
13F-HR
|
8/14/2014 |
000110465914061102 |
|
Q1 2014
|
64 |
2,431,061 |
AMGN, BIIB, GILD, TMO
|
13F-HR
|
5/14/2014 |
000110465914038454 |
|
Q4 2013
|
59 |
2,318,883 |
BIIB, GILD, AMGN, CELG
|
13F-HR
|
2/12/2014 |
000110465914008562 |